FDAnews
www.fdanews.com/articles/102502-regeneron-closes-312-million-common-stock-sale

Regeneron Closes $312 Million Common Stock Sale

December 20, 2007
Regeneron Pharmaceuticals, Inc. announced that following early termination of the Hart-Scott-Rodino waiting period, the company closed the sale of 12 million newly issued shares of Regeneron common stock to the sanofi-aventis Group at a price of $26.00 per share pursuant to its previously announced agreement.
Fox Business